Blockade of μ-opioid receptor-mediated G-protein activation and antinociception by TRK-820 in mice

European Journal of Pharmacology

Volumn 461, Issue 1, 2003, Pages 35-39

  Mizoguchi, Hirokazu ^a   Hung, Kuei Chun ^a   Leitermann, Randy ^a   Narita, Minoru ^b   Nagase, Hiroshi ^c   Suzuki, Tsutomu ^b   Tseng, Leon F ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b HOSHI UNIVERSITY   (Japan)

^c TORAY INDUSTRIES INC   (Japan)

Author keywords

(Mouse); Antinociception; G protein activation; opioid receptor; opioid receptor

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIO)TRIPHOSPHATE; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR ANTAGONIST; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; NALFURAFINE; NORBINALTORPHIMINE; PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; MEMBRANE BINDING; MONITORING; NONHUMAN; PONS; PRIORITY JOURNAL; TAIL FLICK TEST;

EID: 0037423076     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01299-8     Document Type: Article

References (21)

1. Chen Y., Mestek A., Liu J., Hurley A., Yu L. Molecular cloning and functional expression of a μ-opioid receptor from rat brain. Mol. Pharmacol. 44:1993;8-12.
2. D'Amour F.E., Smith D.L. A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther. 72:1941;74-79.
3. Endoh T., Matsuura H., Tajima A., Izumimoto N., Tajima C., Suzuki T., Saitoh A., Suzuki T., Narita M., Tseng L., Nagase H. Potent antinociceptive effects of TRK-820, a novel κ-opioid receptor agonist. Life Sci. 65:1999;1685-1694.
4. Endoh T., Tajima A., Suzuki T., Kamei J., Suzuki T., Narita M., Tseng L., Nagase H. Characterization of the antinociceptive effects of TRK-820 in the rat. Eur. J. Pharmacol. 387:2000;133-140.
5. Evans C.J., Keith D.E. Jr., Morrison H., Magendzo K., Edwards R.H. Cloning of a δ opioid receptor by functional expression. Science. 258:1992;1952-1955.
6. Funada M., Suzuki T., Narita M., Misawa M., Nagase H. Blockade of morphine reward through the activation of κ-opioid receptors in mice. Neuropharmacology. 32:1993;1315-1323.
7. Haley M.J., McCormick W.G. Pharmacological effects produced by intracerebral injection of drugs in the conscious mice. Br. J. Pharmacol. 12:1957;12-15.
8. Kieffer B.L., Befort K., Gaveriaux-Ruff C., Hirth C.G. The δ-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc. Natl. Acad. Sci. U. S. A. 89:1992;12048-12052.
9. Mizoguchi H., Narita M., Nagase H., Tseng L.F. Activation of G-proteins in the mouse pons/medulla by β-endorphin is mediated by the stimulation of μ- and ε-receptors. Life Sci. 67:2000;2733-2743.
10. Nagase H., Hayakawa J., Kawamura K., Kawai K., Takezawa Y., Matsuura H., Tajima C., Endo T. Discovery of a structurally novel opioid κ-agonist derived from 4,5-epoxymorphinan. Chem. Pharm. Bull. 46:1998;366-369.
11. Narita M., Mizoguchi H., Narita M., Sora I., Uhl G.R., Tseng L.F. Absence of G-protein activation by μ-opioid receptor agonists in the spinal cord of μ-opioid receptor knockout mice. Br. J. Pharmacol. 126:1999;451-456.
12. Narita M., Mizoguchi H., Narita M., Dun N.J., Hwang B.H., Endoh T., Suzuki T., Nagase H., Suzuki T., Tseng L.F. G-protein activation by endomorphins in the mouse periaqueductal gray matter. J. Biomed. Sci. 7:2000;221-225.
13. Seki T., Awamura S., Kimura C., Ide S., Sakano K., Minami M., Nagase H., Satoh M. Pharmacological properties of TRK-820 on cloned μ-, δ- and κ-opioid receptors and nociceptin receptor. Eur. J. Pharmacol. 376:1999;159-167.
14. Sim L.J., Selley D.E., Xiao R., Childers S.R. Differences in G-protein activation by μ- and δ-opioid, and cannabinoid, receptors in rat striatum. Eur. J. Pharmacol. 307:1996;97-105.
15. 35S]thio)triphosphate to NG108-15 cell membranes: characterization of agonist and inverse agonist effects. J. Pharmacol. Exp. Ther. 283:1997;1276-1284.
16. 35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol. Pharmacol. 47:1995;848-854.
17. Tsuji M., Takeda H., Matsumiya T., Nagase H., Yamazaki M., Narita M., Suzuki T. A novel κ-opioid receptor agonist, TRK-820, blocks the development of physical dependence on morphine in mice. Life Sci. 66:2000;PL353-PL358.
18. Tsuji M., Yamazaki M., Takeda H., Matsumiya T., Nagase H., Tseng L.F., Narita M., Suzuki T. The novel κ-opioid receptor agonist TRK-820 has no affect on the development of antinociceptive tolerance to morphine in mice. Eur. J. Pharmacol. 394:2000;91-95.
19. Tsuji M., Takeda H., Matsumiya T., Nagase H., Narita M., Suzuki T. The novel κ-opioid receptor agonist TRK-820 suppresses the rewarding and locomotor-enhancing effects of morphine in mice. Life Sci. 68:2001;1717-1725.
20. Yasuda K., Raynor K., Kong H., Breder C.D., Takeda J., Reisine T., Bell G.I. Cloning and functional comparison of κ and δ opioid receptors from mouse brain. Proc. Natl. Acad. Sci. U. S. A. 90:1993;6736-6740.
21. 35S]GTPγS binding to membranes: determination of potencies and efficacies of ligands. J. Pharmacol. Exp. Ther. 282:1997;676-684.